bioMerieux targets breast cancer theranostics with Ipsen
This article was originally published in Clinica
Marcy l'Etoile-based diagnostics company bioMerieux is to collaborate with fellow French pharmaceutical firm Ipsen on diagnostic-and-therapy solution for breast cancer patients. Under the agreement, bioMerieux will develop a test to determine which patients are best suited to benefit from a new breast cancer drug, BN83495, that Paris-based Ipsen is currently investigating. The test, based on bioMerieux's NucliSENS EasyQ molecular diagnostics platform, will be used in the clinical development of the Ipsen drug and for diagnostic purposes, with the potential for future commercialisation. According to WHO figures, breast cancer is the most prevalent form of cancer worldwide with 1.1 million new cases diagnosed each year. The disease is responsible for over 500,000 deaths each year.